Abstract: The purpose of the present invention is to provide a cyclic peptide having any unit structure selected from the structures represented by the following formula (1): —X1—X2—X3—X4—X5—??(1) (in the formula (1), X1 is I, V or L, or an N-alkylamino acid thereof, X2 is S or T, or an N-alkylamino acid thereof, X3 is K or an N-alkylamino acid thereof, X4 is W or an N-alkylamino acid thereof, and X5 is W, Y, or H, or K or an N-alkylamino acid thereof), or a pharmaceutically acceptable salt of the cyclic peptide.

Abstract: A screen transition diagram creator that creates a screen transition diagram illustrating complicated transition relations in an easy-to-understand manner, including: a screen transition diagram editor providing the screen transition diagram in which transition relations among plural screens are illustrated by plural screen nodes and arrows between the screen nodes; a screen transition pattern applying unit applying a predetermined screen transition pattern to a target screen node group that includes at least part of the screen nodes illustrated in the screen transition diagram to provide a pattern-applied screen node group; and a screen transition structure diagram creator creating a screen transition structure diagram by abridgement processing on the pattern-applied screen node group according to a display layout corresponding to the screen transition pattern.

Abstract: A monitoring control system includes a control device that performs a device control process, and a high-order system that monitors the device control process. The control device includes a control CPU that performs the device control process, and an information CPU that is connected to the control CPU via an internal bus. The control CPU includes a device memory that stores therein device data to be used for the device control process, the device data being related to the device. The information CPU includes a built-in database and a data collection unit. The data collection unit performs a data collection process of reading the device data from the device memory via the internal bus, and storing the read device data in the built-in database.

Abstract: A monitoring control system includes a control device that performs a device control process, and a high-order system that monitors the device control process. The control device includes a control CPU that performs the device control process, and an information CPU that is connected to the control CPU via an internal bus. The control CPU includes a device memory that stores therein device data to be used for the device control process, the device data being related to the device. The information CPU includes a built-in database and a data collection unit. The data collection unit performs a data collection process of reading the device data from the device memory via the internal bus, and storing the read device data in the built-in database.

Abstract: A screen transition diagram creator that creates a screen transition diagram illustrating complicated transition relations in an easy-to-understand manner, including: a screen transition diagram editor providing the screen transition diagram in which transition relations among plural screens are illustrated by plural screen nodes and arrows between the screen nodes; a screen transition pattern applying unit applying a predetermined screen transition pattern to a target screen node group that includes at least part of the screen nodes illustrated in the screen transition diagram to provide a pattern-applied screen node group; and a screen transition structure diagram creator creating a screen transition structure diagram by abridgement processing on the pattern-applied screen node group according to a display layout corresponding to the screen transition pattern.

Abstract: An object of the present invention is to provide a drug for promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.

Abstract: Methods of promoting liver morphogenesis prior to the functioning of blood vessels by culturing liver cells with endothelial cells is provided. Also provided are cell cultures and method of promoting vasculogenesis of liver tissue by contacting liver cells with endothelial cells.

Abstract: Provided are a pharmaceutical composition which enhances the sensitivity of a cancer to a molecular target drug, such as gefitinib and erlotinib, wherein the cancer has resistance to the molecular target drug, and a cancer therapeutic agent effective against a cancer having resistance to a molecular target drug, such as gefitinib and erlotinib. The pharmaceutical composition comprising an HGF-MET receptor pathway inhibitor enhances the sensitivity of a cancer to a molecular target drug, such as gefitinib and erlotinib, even though the cancer has resistance to the molecular target drug. The cancer therapeutic agent comprising a molecular target drug in combination with an HGF-MET receptor pathway inhibitor is effective against a cancer having resistance to the molecular target drug.

Abstract: The invention provides a modified glycosylation-deficient HGF and a production method thereof. The glycosylation-deficient HGF is produced by introducing amino acid mutation(s) so that no glycosylation take place at at least one glycosylation site of hepatocyte growth factor.

Abstract: A pharmaceutical preparation comprising a hepatocyte growth factor or a DNA molecule encoding the same and the like according to the present invention can suppress the fibrosis of a transplanted organ after organ transplantation. The present invention is useful in the fields of organ transplantation and regeneration therapy.

Abstract: An HGF precursor protein variant, in which a peptide structure comprises a sequence including a peptide chain X inserted between an ? chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the C-terminus of the ? chain are deleted, and a ? chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the N-terminus of the ? chain are deleted; wherein (i) the peptide chain X has an amino-acid sequence of at least two residues, (ii) the peptide chain X can be cleaved by a protease reaction or a chemical reaction, and (iii) a protein obtained by cleaving at least one site of the peptide chain X has HGF action.

Abstract: A pharmaceutical preparation comprising a hepatocyte growth factor or a DNA molecule encoding the same and the like according to the present invention can suppress the fibrosis of a transplanted organ after organ transplantation. The present invention is useful in the fields of organ transplantation and regeneration therapy.

Abstract: Provided are a pharmaceutical composition which enhances the sensitivity of a cancer to a molecular target drug, such as gefitinib and erlotinib, wherein the cancer has resistance to the molecular target drug, and a cancer therapeutic agent effective against a cancer having resistance to a molecular target drug, such as gefitinib and erlotinib. The pharmaceutical composition comprising an HGF-MET receptor pathway inhibitor enhances the sensitivity of a cancer to a molecular target drug, such as gefitinib and erlotinib, even though the cancer has resistance to the molecular target drug. The cancer therapeutic agent comprising a molecular target drug in combination with an HGF-MET receptor pathway inhibitor is effective against a cancer having resistance to the molecular target drug.

Abstract: An object of the present invention is to provide a drug for promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.

Abstract: A pharmaceutical preparation comprising a hepatocyte growth factor or a DNA molecule encoding the same and the like according to the present invention can suppress the fibrosis of a transplanted organ after organ transplantation. The present invention is useful in the fields of organ transplantation and regeneration therapy.

Abstract: An HGF precursor protein variant, in which a peptide structure comprises a sequence including a peptide chain X inserted between an ? chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the C-terminus of the ? chain are deleted, and a ? chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the N-terminus of the ? chain are deleted; wherein (i) the peptide chain X has an amino-acid sequence of at least two residues, (ii) the peptide chain X can be cleaved by a protease reaction or a chemical reaction, and (iii) a protein obtained by cleaving at least one site of the peptide chain X has HGF action.

Abstract: An HGF precursor protein variant, in which a peptide structure comprises a sequence including a peptide chain X inserted between an ? chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the C-terminus of the ? chain are deleted, and a ? chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the N-terminus of the ? chain are deleted; wherein (i) the peptide chain X has an amino-acid sequence of at least two residues, (ii) the peptide chain X can be cleaved by a protease reaction or a chemical reaction, and (iii) a protein obtained by cleaving at least one site of the peptide chain X has HGF action.

Abstract: A neovascularization promoting composition, a granulation formation-promoting composition and a preventive or curative composition for skin ulcer, comprising a human recombinant HGF wherein five amino acid residues are deleted in the first Kringle domain thereof. The provided compositions of the present invention are useful as a drug capable of promoting granulation formation and neovascularization and being effective in tissue restoration, especially as a preventive and curative agent for skin ulcer.

Abstract: The present invention provides a segment of glycosylation-deficient HGF having mutation(s) introduced into an amino acid sequence so as to prevent glycosylation at at least one glycosylation site of a hepatocyte growth factor (HGF), and a method of producing the same. The segment of glycosylation-deficient HGF of the present invention has the same activity as that of a segment of glycosylated HGF, therefore, it is useful as an alternate for a segment of glycosylated HGF.

Abstract: The invention provides a modified glycosylation-deficient HGF and a production method thereof. The glycosylation-deficient HGF is produced by introducing amino acid mutation(s) so that no glycosylation take place at at least one glycosylation site of hepatocyte growth factor.